Company news

Shin Nippon Biomedical Laboratories, Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)

August 4, 2026

Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache

November 5, 2025

ガバナンスに関するデータ

August 26, 2025

Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting

June 19, 2025

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

April 29, 2025

環境に関するデータ

August 27, 2024

社会（健康経営）に関するデータ

August 27, 2024

社会に関するデータ

August 27, 2024

英語版 株主通信（2023/04/01~2023/09/30）を発行しました

December 26, 2023

Notice Regarding Revisions of the Earnings Forecasts for the Six Months and Full-Year of the Fiscal Year Ending March 31, 2023

July 29, 2022

Shin Nippon Biomedical Laboratories: Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2023 (Under Japanese GAAP)

July 29, 2022

Notice Regarding Revisions of Consolidated Earnings and Dividend Forecasts for the Full-Year of the Fiscal Year Ending March 31,2022

February 2, 2022

Supplementary Material on 1H Financial Results

November 3, 2021

Notice Regarding Revisions of the Earnings Forecasts for the Six Months and Full Year of the Fiscal Year Ending March 31, 2022

October 21, 2021

Notice Regarding Establishment of SDGs Committee

August 26, 2021

Health & Productivity Award 2019

February 26, 2019

Shin Nippon Biomedical Laboratories: SNBL will give a preclinical seminar in Taiwan

January 17, 2019

2018 Prime Minister's Award

December 21, 2018

MHLW Award of Excellence

December 2, 2018

Decks